DJIA 17,084.49 33.74 0.20%
NASDAQ 4,830.47 19.68 0.41%
S&P 500 2,014.89 1.46 0.07%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

32.86 -0.39 (-1.17%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

RHHBY $32.86 -1.17%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $33.17
Previous Close $33.25
Daily Range $32.73 - $33.21
52-Week Range $31.50 - $38.54
Market Cap $184.7B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.5%)
Volume 806,448
Average Daily Volume 1,629,974
Current FY EPS $1.85





Roche Holding Ltd. (ADR) (RHHBY) Description


News & Commentary Rss Feed

Lung Cancer Treatment Gets Personal

After years of languishing survival rate improvements in lung cancer, new personalized therapies yield hope of a dramatic boost in response rates and survival.

How Much Could Exelixis Really Be Worth?

One shareholder takes a stab at adding up the individual components of Exelixis' product portfolio and pipeline to estimate its fair value.

This Cancer Immunotherapy News Is Going to Turn Some Heads

Cancer giant Roche may have been beaten to pharmacy shelves by other cancer immunotherapies, but data from two studies involving atezolizumab this past weekend is going to turn some heads.

Amgen Gets a Step Closer to a Multibillion-Dollar Market

Amgen and Allergan's ABP 215 biosimilar to Avastin posted positive results in phase 3 trials.

Can You Name the Company Leading the Charge in Cancer Care Research?

This company currently has 80 clinical studies directly focused on treating cancer. Can you name it?

A Reduced Payout Could Be in the Cards for These High-Yield Dividend Stocks

GlaxoSmithKline and PDL BioPharma offer investors sector-crushing yields at current levels. But there's good reason to believe they won't last much longer.

Pfizer Is in Talks to Acquire GlaxoSmithKline

Pfizer is among several potential bidders rumored to be in talks with the London-based pharmaceutical giant regarding a possible takeover.

3 Stocks to Take Advantage of the Rise in Personalized Medicine

Companies are working hard to tailor healthcare to individuals. Find out which stocks have been most successful.

Why Exelixis, Inc. Shares Slumped Today

Exelixis Inc.'s FDA review for approval of cobimetinib has been delayed until November.

The Drug Development Process Explained in Detail and How It Impacts Your Investments

A detailed step-by-step guide on how a drug goes from a concept in the lab to a product on pharmacy shelves, and how the drug development process can affect your investments.

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $32.86 (-1.17%)
Current stock: RHHBY
JNJ $95.37 (0.31%)
Current stock: JNJ
NVS $91.90 (-0.77%)
Current stock: NVS
GSK $40.22 (0.15%)
Current stock: GSK